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SUMMARY
The brain cancer medulloblastoma consists of
different transcriptional subgroups. To characterize
medulloblastoma at the phosphoprotein-signaling
level, we performed high-throughput peptide phos-
phorylation profiling on a large cohort of SHH (Sonic
Hedgehog), group 3, and group 4medulloblastomas.
We identified two major protein-signaling profiles.
One profile was associated with rapid death post-
recurrence and resembled MYC-like signaling for
which MYC lesions are sufficient but not necessary.
The second profile showed enrichment for DNA dam-
age, as well as apoptotic and neuronal signaling.
Integrative analysis demonstrated that heteroge-
neous transcriptional input converges on these pro-
tein-signaling profiles: all SHH and a subset of group
3 patients exhibited the MYC-like protein-signaling
profile; the majority of the other group 3 subset and
group 4 patients displayed the DNA damage/
apoptotic/neuronal signaling profile. Functional anal-
ysis of enriched pathways highlighted cell-cycle pro-
gression and protein synthesis as therapeutic targets
for MYC-like medulloblastoma.
INTRODUCTION
The overall cure rate for pediatric cancer has increased to
approximately 80% over the past decades, yet there is an urgent
need for further improvements (Pui et al., 2011). Current treat-
ment strategies depend heavily on cytotoxic agents and radio-
therapy, causing major side effects that have severe impact on
the quality of life of survivors (Spiegler et al., 2004). Further,
some pediatric malignancies remain difficult to target and have
a dismal prognosis (Hassan et al., 2017). Recent efforts to map
all pediatric cancer genomes have provided a tremendous
wealth of information on the (epi)genetic background of the
various pediatric cancer types (Downing et al., 2012). Not only
is this knowledge highly valuable for classification and diag-
nostic purposes, but it also offers unprecedented potential for
the development of new therapies and precision medicine.
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Medulloblastoma, a malignant brain cancer that arises in the
cerebellum, is one of the pediatric cancer types that has been
the subject of intense investigation. Originally classified as a sin-
gle disease, there is now consensus that, based on gene expres-
sion patterns, four main molecular medulloblastoma groups
exist with different biological and clinical characteristics: WNT,
SHH (Sonic Hedgehog), group 3, and group 4 (reviewed in Taylor
et al., 2012). These groups can be further subdivided when
combining different profiling strategies, such as gene expression
analysis, genome-wide DNAmethylation patterns, somatic copy
number alterations and mutations, and clinical features, demon-
strating considerable heterogeneity within medulloblastoma
subgroups that is also recognized by the current World Health
Organization (WHO) classification of central nervous system tu-
mors (Cavalli et al., 2017; Louis et al., 2016; Northcott et al.,
2017). Based on these studies, SHHmedulloblastoma harboring
TP53 mutations and MYC-amplified, metastasized group 3 me-
dulloblastoma have the worst prognosis (Cavalli et al., 2017;
Ramaswamy et al., 2016).
A less explored aspect in medulloblastoma research is the role
of the tumor proteome, which turns (epi)genetic information into
function (Anagnostopoulos et al., 2015; Staal et al., 2015). Part of
the proteome constitutes the protein-signaling network that
transduces and interprets signals required for faithful execution
of most cellular processes (Aebersold and Mann, 2016). Disrup-
tions in signaling routes implicated in cancer endow the cells
with a growth advantage contributing to tumor growth (Hanahan
and Weinberg, 2011). Various rational therapies that directly
target proteins in these networks have been applied in patients,
albeit with limited success (de Bono and Ashworth, 2010; Hana-
han, 2014). Acquired resistance and rewiring of the protein-
signaling networks toward parallel routes might be factors
that contribute to the limited anti-tumor effect of these drugs.
Therefore, it is essential to study protein signaling at the sys-
tems-biology level. This will deepen our understanding of protein
networks, contribute to the development of novel therapies tar-
geting all parallel signaling routes, and shed light on the chan-
neling of (epi)genetic information into protein biology.
Here, we report the integration of transcriptional and genetic
profiling with high-throughput peptide phosphorylation profiling
as a measure for overall kinase activity, across a large cohort
of untreated SHH, group 3, and group 4 medulloblastoma sam-
ples. Remarkably, medulloblastoma peptide phosphorylation
profiling revealed two significant phosphoprotein-signaling pro-
files, while the cohort contained three different medulloblastoma
subgroups based on gene expression. The first protein-signaling
profile was reminiscent of signaling induced by the MYC onco-
protein that could occur in the absence of MYC aberrancies
and was associated with rapid death post-recurrence. The sec-
ond profile exhibited increased neuronal, apoptotic, and DNA-
damage signaling. Functional analysis highlighted cell-cycle
transition and protein synthesis as actionable targets in MYC-
like medulloblastoma. Altogether, our data suggest that, despite
heterogeneity at the genetic and transcriptional levels, down-
stream signaling in medulloblastoma ultimately converges on a
limited number of potentially targetable signaling pathways,
and they highlight that protein signaling constitutes a unique
layer of information.
RESULTS
High-Throughput Peptide Phosphorylation Profiling
Reveals Two Major Medulloblastoma Protein-Signaling
Profiles
The main goal of our study was to gain insight into medulloblas-
toma protein signaling by performing high-throughput peptide
phosphorylation profiling and subsequent integration with ge-
netic and transcriptional profiling (Figure 1A). Untreatedmedullo-
blastoma samples were collected at diagnosis from three Dutch
university medical centers. They were subjected to targeted
exon sequencing of selected cancer-related genes (n = 49 out
of 50 tumors), interphase fluorescence in situ hybridization
(FISH; n = 42/50), transcriptional profiling (n = 48/50), and pep-
tide phosphorylation profiling (n = 50/50) (Figure 1A). Clinical
data were available for gender, patient age, and metastasis at
diagnosis; treatment protocol; relapse; and survival (Table S1).
Transcriptome analysis and unsupervised hierarchical clustering
of differentially expressed genes showed that our patient cohort
consisted of SHH (n = 13), group 3 (n = 16), and group 4 (n = 19)
patients (Figures 1B and S1A). There were noWNT group tumors
present in our cohort, likely due to their low frequency (Northcott
et al., 2012). In agreement with previous findings, males were
overrepresented in our cohort, and the transcriptomes of
younger patients were generally assigned to SHH and group 3
(Figure 1C). Metastatic disease wasmost frequent in group 4 pa-
tients and associated with adverse outcome (Figures 1C, 1D,
and S1B). There was no significant difference in survival between
subgroups (Figure S1C).
We subjected protein lysates from all medulloblastoma sam-
ples to peptide phosphorylation profiling, using commercially
available PTK (protein tyrosine kinase) and STK (serine/threonine
kinase) PamChip arrays. These arraysmeasure the phosphoryla-
tion of synthetic peptides containing known substrate recogni-
tion sites for PTKs (n = 143 peptides) and STKs (n = 142 peptides)
in a high-throughput fashion (Figure S2A). Unsupervised hierar-
chical clustering analysis using either the PTK or STK array iden-
tified the presence of two major protein-signaling profiles that
consisted of peptides with relatively high phosphorylation inten-
sity. These signaling profiles separated the tumors into protein-
signaling clusters 1 and 2 that were largely overlapping between
the STK and the PTK arrays (Figures 2A and S2B–S2D; Table S2).
This was unexpected, given our earlier unpublished observa-
tions in a different type of brain cancer, glioblastoma, in which
peptide phosphorylation profiling yielded multiple complex
signaling profiles that did not correlate with subtype, survival,
age, or gender (Figure S2E; Tables S1 and S2).
We noticed that there was a marked difference in the level of
peptide phosphorylation intensities within STK protein-signaling
cluster 1 samples. To address its biological relevance, based on
branching of the clustering tree, we divided samples with the
highest similarity in peptide phosphorylation intensities into sub-
clusters 1A and 1B (Figures 2A, S2B, and S2C). Patients in sub-
cluster 1A had a very low survival compared to the other patients,
indicating the predictive value for this subcluster (p = 0.0058)
(Figures 2B and S2F).
We then set out to further explore the biology of the protein-
signaling profiles. Most peptides showing relatively high
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phosphorylation levels in protein-signaling profile 1 have low
phosphorylation of highly phosphorylated profile 2 peptides,
and vice versa, which is suggestive of binary signaling states
in medulloblastoma (Figure 2A). To identify the putative
signaling pathways underlying these two states, we performed
functional annotation of our signaling profiles using the Data-
base for Annotation, Visualization and Integrated Discovery
(DAVID) and visualized enriched processes using the Cyto-
scape Enrichment Map app (Figures 2C, S3, and S4; Table
S2). While we did not identify clear, cluster-specific enriched
pathways in the PTK protein-signaling profiles, we found that
STK protein-signaling profile 1 displayed enrichment for cell-
cycle transition and G-protein-coupled receptor signaling and
that STK protein-signaling profile 2 was mostly enriched for
DNA-damage response/p53 signaling, apoptotic signaling,
response to external stimuli, and neuronal signaling (Figures
2C, S3, and S4). This is in line with the STKs constituting a larger
fraction of the kinome and functioning in more diverse signaling
pathways compared to PTKs. Further analyses, therefore,
focused on STK protein signaling.
Medulloblastoma Protein-Signaling Clusters Partially
Overlap with Molecular Subgroups
We next wanted to address the relationship between the previ-
ously established transcriptional medulloblastoma subgroups
and our protein-signaling medulloblastoma clusters. Hereto,
Figure 1. Overview of the Workflow and
Medulloblastoma Patient Cohort Character-
istics
(A) Overview of the workflow. N = 50 medullo-
blastoma samples from three Dutch university
medical centers were included in the study. DNA
(n = 49/50 tumors), nuclei (n = 42), mRNA (n = 48),
and protein (n = 50) were isolated and analyzed for
genetic alterations, gene expression, and peptide
phosphorylation activity, respectively. Datasets
were compared by integrative analysis.
(B) Pie chart showing themolecular subgrouping of
N = 50 medulloblastoma patients (red indicates
SHH, yellow indicates group 3, green indicates
group 4, and white indicates ND [not determined]).
(C) Bar diagrams showing patient gender, age, and
metastasis per molecular subgroup (M0, no
metastasis; M+, metastasis at diagnosis).
(D) Kaplan-Meier curve showing the survival of me-
dulloblastoma patients with (M+, red) and without
(M0, blue) metastasis at diagnosis. The p values
were determined using a log-rank (Mantel-Cox) test,
and p < 0.05 was considered significant.
See also Figure S1 and Table S1.
we first investigated how the transcrip-
tionally defined medulloblastoma sub-
groups (i.e., SHH, group 3, and group
4) distributed across the protein-
signaling clusters. We divided group 3
tumors into subgroups 3A and 3B due
to marked transcriptional heterogeneity
and in agreement with earlier findings
describing overlap in transcriptomes between subsets of
group 3 and group 4 medulloblastoma (Figure S1A) (Kool
et al., 2008; Taylor et al., 2012). We found that SHH tumors
were exclusively in protein-signaling cluster 1. Group 3 tumors
were enriched in cluster 1, whereas group 4 tumors were pre-
dominantly found in protein-signaling cluster 2 (Figure 3A).
Fifty-one peptides correlated significantly with the SHH group,
4 peptides correlated with group 3A, 1 peptide correlated with
group 3B, and 76 peptides correlated with group 4 (false dis-
covery rate [FDR] < 0.05; Table S2). We also re-plotted the
data to visualize the protein-signaling profiles per transcrip-
tional subgroup (Figure 3B). These data suggest that gene-
expression-based tumor profiling largely correlates with pro-
tein-signaling profiling. However, there is a subset of group 3
and group 4 tumors that localizes to the opposite protein-
signaling cluster. To investigate whether subtle differences in
gene expression could be underlying this, we plotted medullo-
blastoma transcriptional profiles against the protein-signaling
clusters (Figure 3C). Group 3B, which shares characteristics
with group 4, contained all group-3 tumors exhibiting protein-
signaling profile 2, suggesting that group-4-like gene expres-
sion contributes to this protein-signaling profile. Altogether,
these results demonstrate that gene expression strongly,
though not fully, correlates with protein signaling and, impor-
tantly, that different transcriptional profiles channel into the
same protein-signaling pathway.
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MYC-like Signaling Defines the Main Medulloblastoma
Protein-Signaling Profile and Is Associated with Rapid
Death Post-recurrence
After identifying two protein-signaling profiles in our medullo-
blastoma cohort, we set out to unravel themolecular mechanism
imposing these profiles. We hypothesized that potent (proto)on-
cogenes, inducing replication stress, or lost tumor suppressor
genes are potential candidates. Therefore, we set out by
analyzing the medulloblastoma transcriptome data for expres-
sion levels of theMYC oncogenes and the TP53 tumor suppres-
sor gene, which have been postulated as important players in
medulloblastoma (Figure S5A) (Hill et al., 2015; Kawauchi et al.,
2012; Pei et al., 2012; Roussel and Robinson, 2013). We
observed that a number of tumors in protein-signaling cluster 1
displayed relatively highmRNA expression ofMYC (mainly group
3 tumors), or MYCN (p < 0.001) (mainly SHH tumors), although
this was not true for all tumors. Group 4 tumors showed relatively
lowMYC expression levels. MYCL did not show differential gene
expression. Intriguingly, TP53 expression was significantly
higher in a subset of protein-signaling cluster 1 tumors but low
across cluster 2 (p < 0.001). These observations suggest that
MYC and TP53 could be involved in dictating the protein-
signaling profiles.
To model oncogene-induced replication stress and tumor sup-
pressor function, we made use of an in vitro system of non-
cancerous, diploid human cells (hTERT immortalized retinal pig-
mented epithelial cells, hereinafter called RPE-1). We generated
RPE-1 cell lines overexpressing MYC, MYCN, CCNE1 (CYCLIN
E1), or CDC25A, lesions known to provoke replication stress (Fig-
ures S5B and S5C). These RPE-1 cell lines were either TP53wild-
type, TP53 mutant (insensitive to MDM2 inhibitor Nutlin-3), or
TP53 null (Figures S5C and S5D). Cell lysates from these models
were subjected to peptide phosphorylation profiling on the STK
array and analyzed in amanner similar to that for themedulloblas-
toma patient samples (Figures 4A and S5E; Table S2). The spec-
ificity of this model was validated by provoking differential TP53
responses in wild-type or TP53 null RPE-1 cells using either Nut-
lin-3 or irradiation, which resulted in different protein-signaling
profiles for each condition (Figures S5F and S5G; Table S2). Un-
supervised hierarchical clustering showed that overexpression of
both MYC and MYCN induces a strong shift in the peptide phos-
phorylation profile as compared to empty vector control cells,
which was even more apparent upon loss of p53 function (Fig-
ure 4A). Surprisingly, loss of p53 activity alone yielded a reciprocal
profile reminiscent of control cells, suggesting that this profile re-
sembles baseline protein signaling that is, at least, partially p53
Figure 2. High-Throughput Peptide Phos-
phorylation Profiling Reveals Two Medullo-
blastoma Protein-Signaling Profiles with
Specific Enriched Biological Processes
(A) Heatmap showing the unsupervised hierarchi-
cal clustering of normalized differential peptide
phosphorylation intensities of n = 142 different
synthetic peptides with serine/threonine kinase
(STK) recognition sites across N = 50 medullo-
blastoma samples. Peptides clustered into two
profiles termed protein-signaling profile 1 and
protein-signaling profile 2. Patients clustered into
twomain clusters, termed protein-signaling cluster
1 (gray) and cluster 2 (black). Patient clusters were
further subdivided into subclusters 1A, 1B, and 2.
PTK-based patient clusters were overlaid.
(B) Kaplan-Meier curve showing survival of
medulloblastoma patients in the different STK
protein-signaling (sub)clusters. The p values were
determined using a log-rank (Mantel-Cox) test, and
p < 0.05 was considered significant.
(C) Enrichment map representing biological pro-
cesses enriched in the different protein-signaling
profiles. Each node represents a biological pro-
cess grouped and labeled by biological theme.
Biological processes connected by edges have
proteins in common. Enriched biological pro-
cesses were determined with the Database of
Annotation, Visualization and Integrated Discovery
(DAVID), v.6.8 (Benjamini-corrected q = 0.1, p =
0.01) and visualized with the Enrichment Map app
in Cytoscape.
See also Figures S2, S3, and S4 and Table S2.
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independent. CDC25A and CCNE1 overexpression also induced
profiles similar to those of control, indicating that theMYC onco-
genes are unique in their response. However, when p53 function
is impaired, CCNE1 cells partially shifted toward the MYC profile,
implying that genetic lesions can collaborate to mimic MYC-
induced signaling (Figure 4A).
To test our hypothesis that (onco)genes such as MYC and
TP53 could be sufficiently powerful to impose a medulloblas-
toma protein-signaling profile upon a tumor, we took the pep-
tides showing highest differences in phosphorylation intensity
across all MYC and MYCN RPE-1 samples compared to control
and established the degree of overlap with the relatively high in-
tensity peptides of the medulloblastoma protein-signaling pro-
files (Figure 4B; Table S2). This analysis yielded a 94% overlap
with protein-signaling profile 1 and basically no overlap with pro-
file 2. Comparison with the highest intensity peptides from the
p53 activation experiment showed only a modest overlap
(72%) with signaling profile 2 (Figures 4B and S5G; Table S2).
Hence, we renamed medulloblastoma protein-signaling profile-
1 ‘‘MYC-like’’ and concluded that, whereas TP53 loss might
contribute to this profile, p53 activation status cannot explain
either of the protein-signaling profiles. Interestingly, it has
recently been shown that gain ofMYC and loss of TP53 function
upon recurrence is common and predictive of rapid death due to
progressive disease in medulloblastoma (Hill et al., 2015). When
Figure 3. MedulloblastomaProtein-Signaling
Clusters Partially Overlap with Molecular
Subgroups
(A) Overlap of transcriptional subgroups and pro-
tein-signaling clusters (gray indicates cluster-1,
black indicates cluster-2, red indicates SHH,
yellow indicates group 3A, orange indicates group
3B, and green indicates group 4).
(B) Heatmap showing the supervised hierarchical
clustering of STK peptide phosphorylation array
profiling based on molecular subgrouping.
(C) Heatmap showing unsupervised hierarchical
clustering of gene expression intensities of me-
dulloblastoma samples overlaid with the STK
protein-signaling clusters.
See also Table S2.
we explored time to death post-recur-
rence in our cohort, we observed that pa-
tients with a MYC-like signaling profile
succumbed significantly faster than pa-
tients with the opposite signaling profile
(p = 0.0151) (Figure 4C). This indicates
that protein-signaling profiling can predict
clinically aggressive disease after relapse
already at diagnosis.
MYC Overexpression or
Amplification Is Dispensable for the
MYC-like Medulloblastoma Protein-
Signaling Profile
We had already observed that MYC,
MYCN, and TP53 expression was
elevated in some, but not all, tumors (Figure S5A). We then
wanted to address whether genomic alterations, such as MYC
amplifications or TP53mutations, could underlie the two medul-
loblastoma protein-signaling profiles. Interphase FISH was used
to detect amplifications of theMYC andMYCN gene loci (Figures
5 and S6A). Only 2 out of 42 tumors tested showed amplification
ofMYC. Onewas a group 3medulloblastoma belonging toMYC-
like protein-signaling cluster 1, which hadMYC amplifications in
a substantial number of tumor cells. The other tumor was a group
4 medulloblastoma of protein-signaling cluster 2 with a minor
MYC-amplified subclone. None of the 42 tested tumors had
MYCN amplifications.
Subsequently, we performed targeted exon sequencing to
identify TP53 mutations (Figure 5; Table S4). We hypothesized
that the increased TP53 mRNA expression levels in the MYC-
like tumor cluster are related to mutations in the TP53 gene,
endowing p53 with pro-oncogenic activity (Levine, 1997). In
agreement, we found that the 3 tumors with TP53 point muta-
tions were in the MYC-like protein-signaling cluster. Intrigu-
ingly, one of these patients also had a MYC amplification
and belonged to subcluster 1A, exhibiting poor overall
survival.
Lastly, we attempted to call copy number aberrations based
on transcriptome data, which provides a rough estimate of tu-
mor aneuploidy (Figures 5 and S6B). We could detect a number
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of chromosome arm gains and losses previously associated
with medulloblastoma, such as on chromosomes 1, 7, 8, 9,
10, 16, and 18 (Northcott et al., 2012). Between the two pro-
tein-signaling clusters, the only differential copy number
alterations found were on chromosomes 17 and 21. Of note,
chromosome 17 abnormalities are frequently attributed to
isochromosome 17q/i(17q), which is associated with (partial)
loss of TP53 expression and enriched in our protein-signaling
cluster 2 (Bien-Willner and Mitra, 2014). In conclusion, genetic
alterations are highly associated with changes in mRNA
expression as expected. Together, they explain the protein-
signaling profiles of most, but not all, of the tumors in our
cohort, suggesting that protein signaling constitutes a discrete
informational layer.
Protein-Signaling Profiling Uncovers Therapeutic
Targets for MYC-like Medulloblastoma
Functional annotation of the protein-signaling profiles had iden-
tified enriched pathways for each profile (Figure 2C). We
reasoned that these pathways could be exploited as targets
for treatment, as they likely fulfill key roles in tumor protein
signaling. Two processes enriched in signaling profile 2 were
apoptotic signaling and DNA damage/p53-mediated response.
Considering the relatively low TP53 mRNA expression levels
(Figure S5A), absence of TP53 point mutations, and high inci-
dence of i(17q) in this group (Figure 5), we hypothesized that
increasing p53 activity could have an anti-tumorigenic effect in
these patients (K€unkele et al., 2012). However, all human medul-
loblastoma cell lines that we analyzed on the STK array exhibited
Figure 4. MYC-like Signaling Defines the
Main Medulloblastoma Protein-Signaling
Profile and Is Associated with Rapid Death
Post-recurrence
(A) Heatmap showing the unsupervised hierarchi-
cal clustering of STK peptide phosphorylation in-
tensities in RPE-1 TP53 wild-type and RPE-1 TP53
mutant/TP53 null cells, with or without MYC,
MYCN, CYCLIN E1, and CDC25A overexpression.
EV, empty vector; TP53-mut, TP53 mutant.
(B) Bar plot showing the overlap between peptides
up- or downregulated in medulloblastoma protein-
signaling profiles and peptides up- or down-
regulated in MYC activation or p53 activation
profiles.
(C) Kaplan-Meier curve showing the time from
relapse to death of medulloblastoma patients in
the MYC-like signaling cluster versus signaling
cluster 2. The p values were determined using a
log-rank (Mantel-Cox) test, and p < 0.05 was
considered significant.
See also Figure S5 and Table S2.
a (partial) MYC-like profile, precluding
testing of this hypothesis (Figure S7).
Therefore, we focused on processes en-
riched in the MYC-like signaling profile
and selected cell-cycle progression as a
putative actionable target (Figure 2C).
We reasoned that this process reflects
the replication stress that accompanies MYC-like signaling. It
had been demonstrated previously that oncogene-induced repli-
cation stress sensitizes cells for the suppression of proteins
involved in the G2/M transition, which prompted us to test the
drug sensitivity of medulloblastoma cell lines for inhibitors of
G2/M components ATR and WEE1 (Harris et al., 2014; Schoppy
et al., 2012). We observed that all cell lines were sensitive to the
lead compounds MK-1775 (WEE1 inhibitor) and VE-822 (ATR in-
hibitor) (Figure 6A). Especially the medulloblastoma cell lines
with MYC amplifications (MED8A and HD-MB03) showed high
sensitivity to ATR inhibition.
Lastly, we wanted to address whether the detection of target-
able pathways based on protein-signaling profiling is restricted
to the level of proteins or whether they are also discernable at
the level of the transcriptome. Hereto, we performed supervised
hierarchical clustering of medulloblastoma samples based on
protein-signaling clusters and selected the genes that were
significantly up- or downregulated (p = 5E5) (Figure 6B; Table
S5). The regulated genes, which did not show overlap with pre-
viously published MYC signatures, clustered into two major
groups, each containing one enriched biological theme: protein
synthesis-related processes in MYC-like cluster tumors and
neuronal differentiation processes in signaling cluster 2 tumors
(Figure 6C; Table S5) (Coller et al., 2000; Jung et al., 2017; Val-
entijn et al., 2012). Both themes have previously been recog-
nized as enriched in two or more of the medulloblastoma tran-
scriptional subgroups; however, they have not been singled
out as uniquely correlated with shared protein-signaling profiles
(Kool et al., 2008). Protein synthesis is a process tightly
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associated with MYC function and has been proposed as an
anti-cancer target (van Riggelen et al., 2010; Truitt and Rug-
gero, 2016). Therefore, we performed a proof-of-principle
experiment to test whether our medulloblastoma cell lines
were sensitive to protein synthesis inhibition. As anticipated,
all medulloblastoma cell lines were sensitive to the protein syn-
thesis inhibitor Brusatol; however, MYC-amplified cells were
roughly eight times more sensitive (lethal concentration
[LC50], mean ± SEM: 4.25 nM ± 2.56 nM) than non-MYC ampli-
fied cells (LC50, mean ± SEM: 32.78 nM ± 4.50 nM) (Figure 6D).
DISCUSSION
In this study, we have assessed kinome-wide phosphoprotein-
signaling across a cohort of primary human medulloblastoma.
We identified twomajor protein-signaling profiles, which was un-
expected, given the presence of three molecular medulloblas-
toma subgroups, i.e., SHH, group 3, and group 4. These findings
suggest that different gene expression profiles can coalesce into
common signaling profiles and that protein signaling is a discrete
layer of information that is not directly inferable from tumor
genetics.
Two Protein-Signaling Profiles Delineate Human
Medulloblastoma
It is important to understand the pathways used by tumors
to relay signals, as this will aid the development of targeted
therapies. However, the study of proteins at the systems level
is challenging, due to the limited detection depths of current
techniques, which is particularly relevant for the vast post-
translationally modified proteome (Aebersold and Mann,
2016; Akbani et al., 2014; Sharma et al., 2014). The approach
we have taken is not exhaustive, yet it allows for assessing the
potential activity of a large part of the kinome, thereby yielding
the two broad protein-signaling profiles. Future advancements
in the proteomics field will elucidate whether additional medul-
loblastoma protein-signaling subtypes exist, similar to the
diversification of molecular subtypes that followed from
advanced (epi)genetic profiling (Cavalli et al., 2017; Northcott
et al., 2017).
Figure 5. Summary of Medulloblastoma Patient Clusters, Characteristics, Somatic Mutations, Focal Amplifications, Copy Number Varia-
tions, and mRNA Expression Levels Grouped by the MYC-like Protein-Signaling Cluster
Rows are described from top to bottom. Distribution of protein-signaling clusters (gray indicates MYC-like cluster, and black indicates signaling cluster 2).
Signaling subclusters (white indicates cluster 1A, gray indicates cluster 1B, and black indicates cluster 2). Molecular subgroups (red indicates SHH, yellow
indicates group 3A, orange indicates group 3B, green indicates group 4, and white indicates ND [non-determined]). Patient characteristics (medical center: blue
indicates UMCG, light green indicates RUMC, and light red indicates VUMC; gender: white indicates male, and pink indicates female; age: purple indicates <4
years, and white indicatesR4 years; metastasis: white indicates M0, and orange indicates M+; relapse: green indicates yes, and white indicates no; death: violet
indicates yes, andwhite indicates no). Somaticmutations (red indicatesmutation, andwhite indicates nomutation). Focal amplifications (blue indicates amplified.
and white indicates non-amplified). Large copy number variations (red indicates gain, and blue indicates loss) deduced from gene expression levels. mRNA
expression levels (red indicates high expression, and blue indicates low expression). Missing data are indicated by a black dotted fill. The p values were
determined using a chi-square test or Student’s t test, and p < 0.05 was considered significant. *p < 0.05; **Benjamini-corrected q < 0.05.
See also Figure S6 and Tables S2 and S4.
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A Subset of Medulloblastoma Exhibits a MYC-like
Signaling Profile for which MYC Aberrations Are
Sufficient but Not Necessary
The most frequent protein-signaling profile in the cohort was
highly reminiscent of MYC-induced protein signaling in the
RPE-1 cell-culture model and was, therefore, termed ‘‘MYC-
like.’’ MYC signatures have been described in human cancer,
but based on gene expression and genetic lesions and not on
protein signaling, explaining a lack of overlap with genes in our
MYC-like cluster (Coller et al., 2000; Jung et al., 2017; Valentijn
et al., 2012). Genetic and transcriptional analyses showed that,
for a number of these tumors, amplification or elevated expres-
sion of the MYC family oncogenes could account for the MYC-
like profile, though there were also tumors that did not show
any MYC-related abnormalities, indicating that the MYC-like
signaling profile is not dependent on MYC lesions. From this,
we conclude that MYC-like signaling represents a cell-biological
state that is defined by MYC signaling characteristics but that
can be relayed by other lesions that, alone or in combination,
confer a MYC-like state upon the tumor. In line, in our in vitro
model system, we observed that overexpression of CYCLIN E1
could also evoke a MYC-like profile, but only in combination
with a TP53 alteration. Likewise, the medulloblastoma sample
harboring a PIK3CA point mutation could depend on phosphati-
dylinositol 3-kinase (PI3K) signaling for imposing the MYC-like
protein-signaling profile. The idea that different combinations
of genetic lesions or expression patterns channel into one pro-
tein-signaling profile reconciles our observation that different
medulloblastoma transcriptomes exist within a protein-signaling
cluster. For future studies, it would be interesting to includeWNT
medulloblastomas, which are somewhat paradoxically charac-
terized by high MYC expression while having a favorable prog-
nosis (Roussel and Robinson, 2013).
MYC-like Signaling and Protein Synthesis versus
Apoptotic and Neuronal Signaling: Two Sides of the
Same Coin?
A remaining question is the mechanism behind the second pro-
tein-signaling profile that dominates group 4 medulloblastoma.
We found that this profile is associated with apoptotic signaling,
DNA-damage signaling, and neuronal signaling and differentia-
tion and that it shares features with protein signaling in untrans-
formed, cycling cells. The unequivocally low TP53 mRNA
expression coinciding with a high incidence of i(17q) implies a
Figure 6. Protein-Signaling Profiling Un-
covers Therapeutic Targets for MYC-like
Medulloblastoma
(A) Cell viability assays showing the effects of
WEE1 (MK-1775) and ATR inhibition (VE-822) on
the viability of medulloblastoma cell lines with
different TP53 and MYC genetic backgrounds.
Data points represent mean ± SEM. TP53-mut, cell
lines with TP53 mutations; MYC-amp, cell lines
with MYC amplifications.
(B) Heatmap showing supervised hierarchical
clustering of significantly up- or downregulated
genes (Student’s t test; p < 5E5) in medulloblas-
toma samples belonging to the MYC-like protein-
signaling cluster (gray) versus samples belonging
to protein-signaling cluster 2 (black). The molecu-
lar subgroup assigned to each sample is marked
on top (red indicates SHH, yellow indicates group
3A, orange indicates group 3B, green indicates
group 4, and white indicates ND [not determined]).
(C) Enrichment map representing biological pro-
cesses enriched in profile-specific upregulated
genes (Student’s t test; p < 5E5) for the MYC-like
protein-signaling profile (gray nodes) and protein-
signaling profile 2 (black node). Each node repre-
sents a biological process grouped and labeled by
biological theme. Biological processes connected
by edges have genes in common. Enriched
biological processes were determined with the
Database of Annotation, Visualization and Inte-
grated Discovery (DAVID), v.6.8 (Benjamini-cor-
rected q = 0.1, p = 0.01) and visualized with the
Enrichment Map app in Cytoscape.
(D) Cell viability assays showing the effects of the
protein synthesis inhibitor Brusatol on the viability
of medulloblastoma cell lines with different TP53
and MYC genetic backgrounds. Data points
represent mean ± SEM.
See also Figure S7 and Table S5.
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reduction, but not absence, of functional p53 protein. Therefore,
we hypothesize that part of the profile and oncogenic capacity
of these tumors lies in a partially impaired response of the
TP53 tumor suppressor pathway, hampering apoptosis-
mediated removal of excessive or precociously differentiated
neurons. Enhancing the remaining p53 function, such as by
Nutlin-3 treatment, could be beneficial for these patients.
It should be noted, though, that in the MYC-like cluster, there
are also patients with low TP53 expression or i(17q). How can we
explain that they show the opposite, MYC-like protein-signaling
profile? As an answer to this question, we propose that theMYC-
like profile represents a different side of the same coin. Depend-
ing on levels and context, MYC controls stem cell properties and
differentiation and could, therefore, counteract neuronal differ-
entiation while simultaneously inducing protein synthesis, giving
rise to the MYC-like signaling profile (Akita et al., 2014; Dang,
2012; Fagnocchi and Zippo, 2017; Kim et al., 2010; Leon et al.,
2009). This idea also raises the interesting point that the MYC-
like profile is dominant over the other profile and acts as a switch.
This is supported by our data in RPE-1 cells, in which MYC over-
expression induces a MYC-like signaling state, regardless of
TP53 status. If true, we expect to find evidence of medulloblas-
toma samples switching during tumor progression. Intriguingly,
there is one group 4 patient in protein-signaling cluster 2 who
is positioned at the border between the two clusters. At
diagnosis, this tumor contained a minor clone exhibiting MYC
amplification. It is conceivable that this tumor has adopted
the MYC-like signaling profile upon further clonal selection of
the MYC-amplified cells, which might then have contributed to
the rapid death of this patient.
To definitively prove this point, primary and corresponding
relapse samples should be analyzed. The few studies on rare
medulloblastoma relapse material have shown that, while mo-
lecular subgroups remain stable during progression, histological
and mutational characteristics change upon recurrence, and,
hence, protein-signaling profiles might also switch (Hill et al.,
2015; Morrissy et al., 2016; Ramaswamy et al., 2013; Wang
et al., 2015). Moreover, TP53 pathway defects and MYC gene
family amplifications were the only lesions significantly associ-
ated with relapse and subsequent time to death in all medullo-
blastoma subgroups, which is in line with MYC and TP53 medi-
ating the protein-signaling profiles (Hill et al., 2015).
The MYC-like Signaling Profile Is Associated with Rapid
Death upon Relapse but May Be Targetable
While the overall survival between the two protein-signaling clus-
ters is similar, patientswith aMYC-like profile fareworse if the dis-
ease recurs. Possibly, MYC-like signaling endows the tumor cells
with cancer stemcell properties, including increased resistance to
therapy (Cojoc et al., 2015;Galardi et al., 2016;Wang et al., 2013).
Alternatively, continuous replication stress induces genomic
instability, increasing the mutational burden and clonal heteroge-
neity. Hence, it seems worthwhile to target the MYC-like proper-
ties of these tumors at diagnosis, either by direct MYC inhibition
or by interferencewith downstreamprocesses like cell-cycle tran-
sition and protein synthesis, which we found to be enriched in
MYC-like tumors (van Riggelen et al., 2010; Roussel and Robin-
son, 2013;Soucek et al., 2013; Truitt andRuggero, 2016;Whitfield
et al., 2017). Using medulloblastoma cell lines to model MYC-like
medulloblastoma, we performed proof-of-concept experiments
demonstrating that the targeting of cell-cycle transition or protein
synthesis can attenuate MYC-like medulloblastoma growth
in vitro. Since we used cell lines and lead compounds for our ex-
periments, further clinical testingwill determinewhether suchstra-
tegies are also applicable in patients.
Altogether, we have demonstrated that two major protein-
signaling profiles are present across a cohort of primary medul-
loblastoma samples that are genetically and transcriptionally
heterogeneous. This indicates that (epi)genetic information con-
verges on a limited number of protein-signaling pathways, which
might represent key actionable targets for medulloblastoma
treatment.
EXPERIMENTAL PROCEDURES
Patient Samples
Tumor tissue was obtained from N = 50 untreated primary medulloblastomas
at diagnosis from three Dutch university medical centers (University Medical
Center Groningen, Radboud University Medical Center Nijmegen, and VUUni-
versity Medical Center Amsterdam) by surgical resection. The tissue of N = 30
primary glioblastomas was obtained from the University Medical Center Gro-
ningen by surgical resection. Immediately following surgical resection, tissue
samples were snap frozen in liquid nitrogen and stored at 80C until further
processing. Patient information on gender, age at diagnosis, and subtype is
presented in Table S1. Tumor material was histologically evaluated by an
experienced neuropathologist and examined for tumor content. Samples
were excluded from analysis when tumor content was below 70%. Informed
consent and local medical ethical committee approval was granted for use
of the patient material.
Cell Lines, Cell Culture, and Pharmacologic Inhibition
Human medulloblastoma cell lines RES256, UW402, UW426, and UW473
were kindly provided by Dr. Michael Bobola. UW228, ONS76, MED8A, and
HD-MB03 were kindly provided by Dr. Till Milde. DAOY, D283MED, and
hTERT-immortalized retinal pigmented epithelium cell line (RPE-1) were pur-
chased at the American Type Culture Collection (ATCC). DAOY, RES256,
ONS76, UW228, UW402, UW426, UW473, RPE-1, and MED8A cells were
cultured in DMEM growth medium. The human medulloblastoma cell line
D283MED was cultured in Eagle’s minimal essential medium (EMEM) growth
medium, and HD-MB03 was cultured in RPMI growth medium. All cell lines
were maintained at 37C in a humidified atmosphere of 5% CO2. All growth
media were supplemented with 10% fetal calf serum (GIBCO), 100 U/mL peni-
cillin, and 100 mg/mL streptomycin (GIBCO). Details regarding the origin of hu-
man cell lines used in this paper have been provided in Table S6. RPE-1 cells
were treated with 6 Gy irradiation, MDM2 inhibitor Nutlin-3 (Selleck Chemicals,
S1061) (0–32 mM), etoposide (10 mM), and cisplatin (10 mM); and humanmedul-
loblastoma cell lines were treated with WEE1 inhibitor MK-1775 (Selleck
Chemicals, S1525) (0–2 mM), ATR inhibitor VE-822 (Selleck Chemicals,
S7102) (0–4 mM), or protein synthesis inhibitor Brusatol (Sigma-Aldrich,
SML1868) (0–0.5 mM).
Gene Expression Profiling and Tumor Subgrouping
To generate gene expression profiles, total RNA was hybridized to the Human
HT-12 Expression BeadChip system, v.4 (Illumina) according to the manufac-
turer’s protocol. Gene expression data were extracted and quantile normalized
using custom Perl scripts. To determine the molecular subgrouping of the me-
dulloblastoma samples, unsupervised hierarchical clustering analysis was per-
formed using a variance filter of 0.45 (s/smax) in Qlucore Omics Explorer (v.3.2).
For glioblastoma tumors, subgroups were determined by the presence of the
IDH1R132H mutation (proneural IDH1mut), EGFR amplification combined with
EGFR exon 2–7 deletion (EGFRVIII positive, classical-like), or high expression
of mesenchymal markers (mesenchymal-like) (Conroy et al., 2014).
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Peptide Phosphorylation Profiling
Tyrosine and serine/threonine peptide phosphorylation profiles were deter-
mined using the commercially available PamChip PTK or STK microarray sys-
tem (PamGene). These microarrays consist of n = 143 or n = 142 unique pep-
tide sequences, respectively. Each peptide represents a 13- to 15-amino-acid
sequence corresponding to a phosphorylation site, which serves as a kinase
substrate. Together, these peptides are predicted to cover the activity of
around 65% of the human kinome (13% and 52% for the PTK and STK
PamChip arrays, respectively). The experiment was repeated 3 times for
each medulloblastoma tissue sample. For human cell lines, the experiment
was repeated 1–3 times.
Identification of Somatic Mutations
The mutation status of TP53 was analyzed by next-generation sequencing
using the Illumina TruSight Tumor (TST) 15 assay (Illumina) at the Molecular
Pathology Center of the Jewish General Hospital (Montreal, QC, Canada).
The CAP-compliant clinically validated TST15 assay was performed as per
the supplier’s instructions with 10 ng DNA input. Libraries were sequenced
on the MiSeq Reagent Kit with a v3 flow cell (Illumina). Data were analyzed
with a clinically validated pipeline (NextGENe, SoftGenetics), and variants
were annotated in Geneticist Assistant (SoftGenetics). The International
Agency for Research on Cancer (IARC) TP53 database, v.R18, was consulted
for the molecular interpretation of TP53 variants (http://www.p53.iarc.fr).
Cell Viability Assays
To examine the effect of cell cycle or protein synthesis inhibition, WST-1 color-
imetric viability assays (Roche) were used, following themanufacturer’s proto-
col guidelines. Human medulloblastoma cells were seeded in sextuple at a
density of 10,000 per well in a 96-well plate format. After attachment, cells
were treated with appropriate inhibitor concentrations. All inhibitors were dis-
solved in DMSO and DMSO concentrations were kept constant between the
different conditions. Optical densities were measured using a microplate
reader (Bio-Rad) at 450 nm. Optical densities of wells containing cells were
subtracted by the intensity of a blank control well and normalized relative to
the optical densities of wells containing control-treated cells (100%).
Statistical Analysis
Differences in the expression of individual genes between protein-signaling
profiles or across molecular subgroups were compared using the two-sample
Student’s t test, assuming equal variances. Patient characteristics of patients
belonging to theMYC-like protein-signaling cluster or protein-signaling cluster
2 were compared using a chi-square test. Progression-free survival and overall
survival were analyzed by the Kaplan-Meier method, and p values were re-
ported using the log-rank (Mantel-Cox) test.
Data and Software Accessibility
The accession number for the transcriptome data reported in this paper is
ArrayExpress: E-MTAB-6488. The accession number for the targeted exome
sequencing data reported in this paper is ArrayExpress: E-MTAB-6546. All
original, unprocessed data can be accessed at Mendeley Data (https://doi.
org/10.17632/jkm5vdz42z.1).
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